SIAU
TXG icon

SB Investment Advisers (UK)’s 10x Genomics TXG Stock Holding History

SB Investment Advisers (UK)’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,639,901
Closed -$146M – 5
2020
Q2 		$146M Sell
1,639,901
-2,196,331
-57% -$171M 1.6% 4
2020
Q1 		$239M Buy
+3,836,232
New +$299M 2.58% 5

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VMV
Venrock Management VI Palo Alto, California $47.6M AUM 45.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SB Investment Advisers (UK)'s TXG Position: Q3 2020 in Review

SB Investment Advisers (UK) sold out of 10x Genomics (TXG) in Q3 2020, closing a stake of 1,639,901 shares — an estimated $146M sold.

SB Investment Advisers (UK) first reported a position in TXG in Q1 2020 and held it in 2 quarters. The position peaked at $239M in Q1 2020. 219 funds tracked by Wall St. Rank hold TXG as of Q3 2020.

  • SB Investment Advisers (UK) reported no remaining 10x Genomics position as of Q3 2020 after selling out during the quarter.
  • SB Investment Advisers (UK) sold 1,639,901 10x Genomics shares in Q3 2020, an estimated $146M.
  • SB Investment Advisers (UK) first reported a position in 10x Genomics in Q1 2020 and held it in 2 quarters.
  • SB Investment Advisers (UK)'s 10x Genomics position peaked at $239M in Q1 2020.
  • 219 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2020.

Based on SB Investment Advisers (UK)'s 13F filing for Q3 2020, filed 16 Nov 2020.